Severin Schwan, outgoing Roche CEO (Georgios Kefalas/Keystone via AP Images)
February 2, 2023 03:18 PM EST
Pharma

Roche writes off $3B+ in pipeline as­sets, $750M for Spark-ac­quired gene ther­a­pies

Paul Schloesser

Associate Editor

Roche faces a down­ward turn in rev­enue this year, writ­ing down or off bil­lions in as­sets, and pre­dict­ing a de­cline in rev­enue from Covid-19 prod­ucts …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

2024's bio­phar­ma win­ners and losers; Ca­griSe­ma falls short; Mer­ck swings Chi­na GLP-1 deal; and more

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

A service from the Financial Times